Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 September 2020 | Story Prof Felicity Burt | Photo Supplied
Prof Felicity Burt in front of the new state-of-the-art biosafety Level (BSL) 3 laboratory.

The University of the Free State’s (UFS) new biosafety Level (BSL) 3 laboratory will allow the university’s world-respected researchers to further advance their research on and surveillance of infectious pathogens, with the ultimate benefit being the improved quality of health for the communities of the Free State and beyond.

That is the word from two leading UFS academics on the completion of the new facility; the BSL 3 laboratory will further enhance the university’s reputation for high-level international research – especially in the field of human pathogens – which will help to prevent disease and lead to better health outcomes.

The UFS Vice-Rector of Research, Professor Corli Witthuhn, stressed how important it is to have a facility of this nature – the only one of its kind in central South Africa – on the Bloemfontein campus, noting that its relevance is even greater, its role more critical now that the world finds itself in the grip of the global COVID-19 pandemic.

Intensify research of the impact on human pathogens

“The new BSL 3 facility – the Pathogen Research Laboratory – promises to intensify our research of the impact on human pathogens, as it allows our South African Research Chairs (SARChl) and other outstanding researchers to broaden the range of microbial pathogens that are being studied, and gain a better understanding of the global disease burden,” she said.

Her sentiments were echoed by the university’s Dean of the Faculty of Health Sciences, Prof Gert van Zyl, who added that the international level of quality research carried out in this facility will contribute to improvement in the disease profile of central South Africa.

“In supporting partners like the Free State Department of Health, this important scientific footprint in disease prevention and treatment will benefit the community at large by improving the quality of health research and delivering the best possible outcomes.”

The BSL 3 facility is supported by a small suite of laboratories for molecular and serological research and is accessible to any UFS researcher or student requiring a high level of pathogen containment. 

Appropriate biosafety and containment measures

Research and handling of infectious viruses and bacteria require appropriate biosafety and containment measures to prevent laboratory workers, personnel, and the environment being exposed to potentially biohazardous agents. 

There are four distinct levels of biosafety (levels one to four), with each having specific biosafety requirements. A BSL 3 laboratory is designed and precision-built to operate under negative pressure, and sees all exhausted air passing through a dedicated filter system to ensure that no pathogens escape into the environment. In addition, researchers wear appropriate personal protective equipment suited to the pathogens under investigation.  

The UFS BSL 3 laboratory is a modular container supplied by Air Filter Maintenance Services International (AFMS) and comprises two repurposed shipping containers. It was built and factory-tested in Johannesburg before being dismantled and relocated to the Bloemfontein Campus, where the containers were lifted by crane over trees and onto a concrete platform. The AFMS installation team then spent a number of days metamorphosing the two containers into a state-of-the-art laboratory, with a mechanical plant room and the ducting that maintains the laboratory under constant negative pressure, cleverly and discretely disguised behind cladding, allowing the structure to blend in with neighbouring buildings.

The need for training young researchers and developing skills

The Pathogen Research Laboratory is managed by Professor Felicity Burt, an arbovirologist with more than 25 years’ experience in handling infectious viruses. 

“Biosafety and biosecurity are essential in the investigation of emerging and infectious pathogens that cause significant disease and fatalities,” Prof Burt said.

“And while COVID-19, pandemic, viruses, vaccines, masks, social distancing, and lockdown were words seldom heard just six months ago, they are sadly now part of our everyday vocabulary,” she added, explaining that the current pandemic is the result of the zoonotic transmission of a virus from a wild animal to humans, with subsequent global spread.

“As this is not the first pandemic and will not be the last, the ongoing potential for the emergence of novel viruses and bacteria underscores the need for training young researchers and developing skills to tackle future outbreaks, develop new vaccines, understanding how pathogens cause disease, and discover alternate ways to mitigate outbreaks. 

“We are thrilled to have a state-of-the-art laboratory that allows us to safely handle those pathogens previously excluded from our research and surveillance programme. This facility positions the UFS to provide young scientists with world-class training and build capacity, now and into the future.”

* Division of Virology, University of the Free State, and NHLS, Bloemfontein, South Africa

News Archive

UFS cardiac team leading with project
2017-05-31

 Description: Cardiac team read more Tags: Cardiac team read more

Prof Peter Schultheiss of the Charité University in Berlin,
Germany, visited the Robert WM Frater Centre for
Cardiovascular Research at the UFS for a study regarding
cardiomyopathy, a significant cause of fatal heart failure
among Africans. From the left are Dr Glen Taylor,
Dr Danie Buys, Prof Makoali Makatoko,
Prof Schultheiss and Prof Francis Smit.
Photo: Rulanzen Martin

A team of cardiac doctors associated with the Robert WM Frater Cardiovascular Research Centre at the University of the Free State’s (UFS) Faculty of Health Sciences has commenced with a pioneering research project regarding idiopathic dilating cardiomyopathy.  

An Afrocentric research focus
Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS and Head of the Frater Centre, describes dilating cardiomyopathy as a heart muscle disease that is quite common, particularly among people of African descent. The disease weakens the heart muscle, which in turn leads to heart failure.

“To date there is no curable treatment for this condition and 50% of patients that have shown heart failure, died within a period of five years. The causes of this condition have been unknown in the majority of patients. But over the past few years major strides have been made where virus infections of the heart muscle or myocarditis have been identified as a possible underlying cause. Various genetic diseases are also linked to it,” says Prof Smit.

International collaborations ensure success
According to Prof Smit, the project is being run in conjunction with Prof Heinz-Peter Schultheiss of the Charité University and the Institute for Cardiac Diagnostics and Therapy in Berlin, Germany.

“We have been working on the project over the past 18 months and I have twice visited Prof Schultheiss in Germany. He is now visiting us in Bloemfontein. We have established a collaborative project focused on patients in central South Africa”.
Prof Schultheiss is a world leader regarding the diagnosis, pathology and treatment of dilating cardiomyopathy, says Prof Smit.

“He brings a lifetime of research experience to Bloemfontein and is internationally renowned as the father of myocardial or heart muscle biopsies.

“His pioneering work on the discipline has led to diagnostic accuracy that has induced purposeful and personalised treatment of dilating cardiomyopathy and has brought about dramatic changes in some subsets of patients’ life expectancy and their cure.”

Solving problems close to home
According to Prof Mokoali Makatoko, Head of the Department of Cardiology, there are more than 1500 new cases of heart failure identified annually at the Universitas Academic Hospital, of which approximately 30% are attributed to cardiomyopathy. “With the use of endomyocardial biopsies the team hopes to treat viruses unique to Southern Africa as well as other underlying causes of dilating cardiomyopathy.”

Prof Stephen Brown, Head of Paediatric Cardiology at the Universitas Academic Hospital, says children suffering from this disease never reach a mature age and those under his supervision will also be undergoing these tests. Various other departments at the UFS will also participate in this project. Profs Makatoko and Brown did the first four endomyocardial biopsies under the management of Prof Schultheiss during the past week. The results will be available in the coming weeks after which the project will be officially launched and patient recruitment will start in earnest.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept